Stock analysts at Oppenheimer started coverage on shares of KemPharm (NASDAQ:KMPH) in a research note issued to investors on Friday. The brokerage set an “outperform” rating on the specialty pharmaceutical company’s stock.
KMPH has been the subject of several other reports. Cowen cut KemPharm from an “outperform” rating to a “hold” rating in a research report on Monday, July 9th. ValuEngine raised KemPharm from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Zacks Investment Research cut KemPharm from a “hold” rating to a “sell” rating in a research report on Wednesday, August 15th. Canaccord Genuity reaffirmed a “buy” rating and issued a $11.00 target price on shares of KemPharm in a research report on Tuesday, August 14th. Finally, CIBC reaffirmed an “outperform” rating on shares of KemPharm in a research report on Friday. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. KemPharm presently has an average rating of “Buy” and a consensus target price of $10.88.
Shares of KMPH traded down $0.18 during mid-day trading on Friday, hitting $4.50. The company’s stock had a trading volume of 6,242 shares, compared to its average volume of 62,135. KemPharm has a one year low of $3.44 and a one year high of $8.40. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of -1.05. The stock has a market capitalization of $79.41 million, a price-to-earnings ratio of -1.52 and a beta of -0.32.
KemPharm (NASDAQ:KMPH) last posted its quarterly earnings data on Friday, August 10th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.96) by $0.31. equities analysts predict that KemPharm will post -3.2 EPS for the current year.
In other news, major shareholder Delaware Street Capital Master bought 304,283 shares of KemPharm stock in a transaction that occurred on Monday, July 30th. The stock was purchased at an average cost of $4.00 per share, with a total value of $1,217,132.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 25.90% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC acquired a new position in KemPharm during the first quarter worth $122,000. Spark Investment Management LLC acquired a new position in KemPharm during the second quarter worth $176,000. Royal Bank of Canada raised its stake in KemPharm by 1,847.1% during the first quarter. Royal Bank of Canada now owns 24,125 shares of the specialty pharmaceutical company’s stock worth $191,000 after acquiring an additional 22,886 shares in the last quarter. Change Path LLC acquired a new position in KemPharm during the first quarter worth $479,000. Finally, JPMorgan Chase & Co. raised its stake in KemPharm by 15,976.2% during the first quarter. JPMorgan Chase & Co. now owns 100,637 shares of the specialty pharmaceutical company’s stock worth $795,000 after acquiring an additional 100,011 shares in the last quarter. Hedge funds and other institutional investors own 39.15% of the company’s stock.
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.